Todos os estudos
RecrutamentoFase II e Fase III (Integrado)Intervencionista

AN OPEN-LABEL, MULTICENTER STUDY IN MALE PEDIATRIC PATIENTS WITH CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD) TO ASSESS THE EFFECTS OF MIN-102 TREATMENT ON DISEASE PROGRESSION PRIOR TO HUMAN STEM CELL TRANSPLANT (HSCT)

Cerebral X-linked adrenoleukodystrophy (CALD) is a rare genetic condition affecting males. It damages myelin, the protective covering around nerves in the brain. Over time, this causes trouble with walking, talking, seeing, and hearing. A stem cell transplant can help, but finding a match and preparing for the procedure takes time. This study tests a new medicine called MIN-102. Researchers want to find out whether taking MIN-102 can stabilise or pause the disease while patients wait for a transplant. Because this is an open-label study, all participants receive the study medicine. Doctors will track health changes through regular clinic visits, physical checks, and brain MRI scans. The main goal is to find out if MIN-102 can protect brain function and stop symptoms from getting worse during this critical period.

Em resumo

Status
Recrutamento
Fase
Fase II e Fase III (Integrado)
Patrocinador
Minoryx Therapeutics S.L.
Meta de inscrição
16
Iniciar
21 Jun 2024

Sobre o que é este estudo?

Cerebral X-linked adrenoleukodystrophy (often shortened to CALD) is a rare inherited condition that mainly affects boys and men. In CALD, the body cannot break down certain fatty substances properly. These fats build up and cause inflammation that strips away the protective coating around nerve cells in the brain. Without this protection, nerve signals slow down, leading to rapid changes in movement, eyesight, speech, and behaviour.

Currently, the main treatment to stop CALD from progressing is a human stem cell transplant. This treatment replaces damaged blood-forming cells with healthy donor cells. However, preparing for a transplant takes time. During this waiting period, the disease can continue to advance, which can lead to permanent nerve damage. Researchers hope that giving a medicine called MIN-102 can act as a shield to help calm brain inflammation and protect nerve cells before transplant surgery.

In this study, doctors want to see if MIN-102 can achieve what they call 'arrested disease'—meaning the rapid worsening of brain damage is stopped. They will monitor changes using detailed MRI scans of the brain and regular physical tests that assess everyday abilities like walking, hearing, and communicating.

Taking part helps scientists understand whether MIN-102 could become a valuable treatment to preserve brain function. Because this is an open-label trial, every participant who joins will receive the active study medicine rather than a dummy treatment (placebo).

Pontos principais

  • The study tests whether MIN-102 can halt disease progression in males with cerebral adrenoleukodystrophy (CALD).
  • It aims to protect brain cells while patients prepare for a future stem cell transplant.
  • Every participant receives the active study medication (there is no placebo).
  • Doctors will carefully monitor brain health using regular MRI scans and nerve function checks.
  • Participation is entirely voluntary and does not replace your standard NHS care options.

Quem pode ser elegível?

This trial is designed for males who have been diagnosed with cerebral adrenoleukodystrophy (CALD) and are being considered for a stem cell transplant. While the trial focuses heavily on young boys, study criteria can vary, so the trial team will confirm the exact age requirements.

To be suitable, participants must be at a stage of the condition where doctors believe pausing the disease could still protect brain function. Participants will also need to be able to have regular brain MRI scans and travel to the study centre for planned check-ups.

People may not be able to join if their condition is too advanced, if they have other serious health problems, or if they have had bad reactions to similar medicines in the past. Your specialist care team can review your medical records to see if this trial matches your situation.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Male diagnosed with cerebral X-linked adrenoleukodystrophy (CALD)
  2. Currently being evaluated or waiting for a stem cell transplant
  3. Able to attend regular hospital visits and undergo brain MRI scans
  4. No other major medical conditions that would make taking part unsafe
  5. Willing to take the study medicine as instructed by the trial team
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you or your child takes part, you will attend regular appointments at a specialised hospital clinic. During these visits, doctors will perform detailed health checks. These include neurological exams to check walking, vision, hearing, and speech. Participants will also have regular brain MRI scans to look closely at changes inside the brain.

The study involves taking the medication MIN-102 regularly as directed by the research team. The study is divided into numbered visits (up to Visit 12 and beyond) over several months to track progress before any planned stem cell transplant. The medical team will also keep in close contact to monitor overall wellbeing and check for any side effects.

Riscos e benefícios potenciais

A potential benefit of joining this study is that MIN-102 may help slow down brain inflammation and pause disease symptoms before a stem cell transplant. Participants will also receive very close, expert medical monitoring throughout the trial. However, because MIN-102 is still being tested, there is no guarantee it will work, and it may cause side effects that the study team will explain in detail. Having frequent clinic visits, blood tests, and MRI scans can also take time and effort. Taking part is completely voluntary, and you are free to leave the study at any point without it affecting your standard NHS care.

Localizações (3)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    Alemanha
  • —
    Não verificado
    França
  • —
    Não verificado
    Espanha

Perguntas frequentes

What is MIN-102?

MIN-102 (also known as leriglitazone) is an experimental medicine designed to reduce inflammation and protect nerve cells in the brain from damage caused by CALD.

Does this trial replace a stem cell transplant?

No. The main aim is to test whether MIN-102 can stabilise the condition and protect the brain before a patient undergoes a stem cell transplant.

Will anyone receive a placebo (dummy drug)?

No. This is an 'open-label' study, which means all participants will receive the active study medicine, MIN-102.

Are MRI scans painful?

MRI scans are painless, but they do require lying very still inside a machine that makes loud tapping noises. Earplugs or headphones are provided, and younger children may be offered gentle sedation if needed.

Can we leave the trial if we change our minds?

Yes. You can withdraw from the study at any time, for any reason. Doing so will not affect the standard medical care you or your child receives.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "AN OPEN-LABEL, MULTICENTER STUDY IN MALE PEDIATRIC PATIENTS …" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.